Andy, Author at BioHealth Innovation

News

August 20, 2023

BioTalk Discusses Breaking Frontiers in Immunotherapy: A Conversation with Bill Enright, CEO and Board Director at Vaccitech

What does it take to pioneer groundbreaking T-cell immunotherapies and vaccines for infectious diseases and cancer? Join us for…

Andy

Love0

BioTalk with Rich Bendis Podcast

August 20, 2023

BioTalk Discusses Breaking Frontiers in Immunotherapy: A Conversation with Bill Enright, CEO and Board Director at Vaccitech

What does it take to pioneer groundbreaking T-cell immunotherapies and vaccines for infectious diseases and cancer? Join us for…

Andy

Love0

News

August 18, 2023

International Delegation from Japan Visits BioHealth Innovation, Inc. in a Bid to Strengthen Biotech Ties

On August 16th, BioHealth Innovation, Inc. (BHI) in Rockville, Maryland, hosted a distinguished group of professionals from Japan, representing the…

Andy

Love0

News

August 14, 2023

FDA Accepts Baltimore’s MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for…

Andy

Love0

News

August 14, 2023

How the BioHealth Capital Region Became a Top 3 BioPharma Cluster: Insights from Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News

How does a BioPharma Cluster ascend the ranks to secure a Top 3 position? What are the key factors…

Andy

Love0

BioTalk with Rich Bendis Podcast

August 14, 2023

How the BioHealth Capital Region Became a Top 3 BioPharma Cluster: Insights from Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News

How does a BioPharma Cluster ascend the ranks to secure a Top 3 position? What are the key factors propelling…

Andy

Love0

News

August 10, 2023

Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III

NEW YORK CITY, NEW YORK and ROCKVILLE, MARYLAND, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NEW YORK CITY, NEW YORK and…

Andy

Love0

News

August 9, 2023

BioBuzz: Catching Up with 2022 Crab Trap Winners Neuroene and Polaris

With federal funding and solutions that address major risks and aim to improve outcomes for warfighters and civilians, Polaris and…

Andy

Love0

News

August 9, 2023

Gaithersburg’s Georgiamune Inc. Achieves US FDA Clearance for Investigational New Drug (IND) Application and Secures $75 Million in Series A Financing

GAITHERSBURG, Md., Aug. 9, 2023 /PRNewswire/ -- Today, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational…

Andy

Love0

News

August 9, 2023

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

GERMANTOWN, Md., Aug. 9, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies…

Andy

Love0

Andy

BioTalk Discusses Breaking Frontiers in Immunotherapy: A Conversation with Bill Enright, CEO and Board Director at Vaccitech

BioTalk Discusses Breaking Frontiers in Immunotherapy: A Conversation with Bill Enright, CEO and Board Director at Vaccitech

International Delegation from Japan Visits BioHealth Innovation, Inc. in a Bid to Strengthen Biotech Ties

FDA Accepts Baltimore’s MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

How the BioHealth Capital Region Became a Top 3 BioPharma Cluster: Insights from Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News

How the BioHealth Capital Region Became a Top 3 BioPharma Cluster: Insights from Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News

Addimmune, a Clinical Stage Hiv-Focused Gene Therapy Company, to go Public Through Business Combination With 10x Capital Venture Acquisition Corp. III

BioBuzz: Catching Up with 2022 Crab Trap Winners Neuroene and Polaris

Gaithersburg’s Georgiamune Inc. Achieves US FDA Clearance for Investigational New Drug (IND) Application and Secures $75 Million in Series A Financing

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

About BioHealth Innovation

Contact

Connect

Andy

About BioHealth Innovation

Contact

Connect

Search